Alison M Michie
Overview
Explore the profile of Alison M Michie including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
1033
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Donnelly H, Ross E, Xiao Y, Hermantara R, Taqi A, Doherty-Boyd W, et al.
Nat Commun
. 2024 Jul;
15(1):5791.
PMID: 38987295
Long-term reconstituting haematopoietic stem cells (LT-HSCs) are used to treat blood disorders via stem cell transplantation. The very low abundance of LT-HSCs and their rapid differentiation during in vitro culture...
2.
Wiesheu R, Edwards S, Hedley A, Hall H, Tosolini M, Fares da Silva M, et al.
EMBO J
. 2024 May;
43(14):2878-2907.
PMID: 38816652
In mice, γδ-T lymphocytes that express the co-stimulatory molecule, CD27, are committed to the IFNγ-producing lineage during thymic development. In the periphery, these cells play a critical role in host...
3.
Patterson S, Massett M, Huang X, Jorgensen H, Michie A
Mol Oncol
. 2024 Mar;
18(9):2234-2254.
PMID: 38459421
Acute myeloid leukaemia (AML) is a clonal haematological malignancy affecting the myeloid lineage, with generally poor patient outcomes owing to the lack of targeted therapies. The histone lysine demethylase 4A...
4.
Scott M, Liu W, Mitchell R, Clarke C, Kinstrie R, Warren F, et al.
Nat Commun
. 2024 Jan;
15(1):651.
PMID: 38246924
Whilst it is recognised that targeting self-renewal is an effective way to functionally impair the quiescent leukaemic stem cells (LSC) that persist as residual disease in chronic myeloid leukaemia (CML),...
5.
Malik N, Hay J, Almuhanna H, Dunn K, Lees J, Cassels J, et al.
Leukemia
. 2023 Sep;
37(12):2414-2425.
PMID: 37775560
Targeted deletion of Raptor, a component of mechanistic target of rapamycin complex 1 (mTORC1), reveals an essential role for mTORC1 in initiation/maintenance of leukemia in a CLL model, resulting from...
6.
Rattigan K, Brabcova Z, Sarnello D, Zarou M, Roy K, Kwan R, et al.
Nat Commun
. 2023 Aug;
14(1):4634.
PMID: 37591854
Deregulated oxidative metabolism is a hallmark of leukaemia. While tyrosine kinase inhibitors (TKIs) such as imatinib have increased survival of chronic myeloid leukaemia (CML) patients, they fail to eradicate disease-initiating...
7.
Lees J, Hay J, Moles M, Michie A
Front Immunol
. 2023 Jun;
14:1179101.
PMID: 37275916
Forkhead box (FOX) class O (FOXO) proteins are a dynamic family of transcription factors composed of four family members: FOXO1, FOXO3, FOXO4 and FOXO6. As context-dependent transcriptional activators and repressors,...
8.
Hay J, Tarafdar A, Holroyd A, Moka H, Dunn K, Alshayeb A, et al.
Cancers (Basel)
. 2022 Dec;
14(23).
PMID: 36497487
B cell antigen receptor (BCR) signalling competence is critical for the pathogenesis of chronic lymphocytic leukaemia (CLL). Defining key proteins that facilitate these networks aid in the identification of targets...
9.
Ianniciello A, Zarou M, Rattigan K, Scott M, Dawson A, Dunn K, et al.
Sci Transl Med
. 2021 Sep;
13(613):eabd5016.
PMID: 34586834
Inhibition of autophagy has been proposed as a potential therapy for individuals with cancer. However, current lysosomotropic autophagy inhibitors have demonstrated limited efficacy in clinical trials. Therefore, validation of novel...
10.
Marmiroli S, Huang X, Serafin V, Michie A
Front Oncol
. 2021 Sep;
11:744009.
PMID: 34485164
No abstract available.